Healthcare Providers and Services
Company Overview of Seattle Children's Hospital
Seattle Children's Hospital operates a child health care and pediatric center in the United States. The company offers adolescent gynecology, medicine, behavioral, and substance abuse programs; and ambulatory infusion, anesthesia, audiology, bioethics consultation, blood disorders, cancer, cardiac surgery, children with special needs, complex care, craniofacial center, critical care medicine, dental medicine, dialysis, eating disorders, endocrinology/diabetes, family advisory council, financial counseling, and gastroenterology services. The company also provides thoracic surgery, genetics, growth and feeding dynamics, gynecology, health information management, hematology, insurance and inter...
4800 Sand Point Way NE
Seattle, WA 98105
Founded in 1907
Key Executives for Seattle Children's Hospital
Chief Executive Officer and Trustee
Chief Financial Officer and Senior Vice President
Surgeon-In-Chief, Senior Vice President, President of CUMG, and Trustee
President of Seattle Children's Hospital Research Institute
President of Seattle Children's Hospital Foundation
Compensation as of Fiscal Year 2017.
Seattle Children's Hospital Key Developments
Seattle Children's Hospital Presents at 69th AACC Annual Scientific Meeting & Clinical Lab Expo, Jul-30-2017
Jul 28 17
Seattle Children's Hospital Presents at 69th AACC Annual Scientific Meeting & Clinical Lab Expo, Jul-30-2017 . Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Jane Dickerson.
Seattle Children's opens the First Clinical Trial Applying Next-Generation T-Cell Receptor
May 23 17
Seattle Children's has opened the first clinical trial applying next-generation T-cell receptor (TCR) sequencing and single-cell gene expression analysis to better understand how the immune system drives both inflammatory bowel disease (IBD) in pediatric autoimmunity patients and graft-versus host disease (GVHD) in pediatric bone marrow transplant (BMT) patients. The PREDICT (Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation) 
trial is expected to first provide clinicians new information about why IBD arises in children, allowing them to tailor treatment plans to each patient. The trial will later expand to include BMT patients with the goal of identifying the immunologic changes that occur when a patient develops GVHD, the deadliest complication
associated with BMT. BMT is used to treat a range of pediatric conditions from leukemia to inherited bone marrow failure syndromes, congenital metabolic disorders and other metabolic diseases.
Seattle Children's Hospital Announces First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults with Leukemia Treated with T-Cell Immunotherapy
May 9 17
After phase 1 results of Seattle Children's Hospital Pediatric Leukemia Adoptive Therapy (PLAT-02) trial have shown T-cell immunotherapy to be effective in getting 93% of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) into complete initial remission, researchers have now opened a first-in-human clinical trial aimed at reducing the rate of relapse after the therapy, which is about 50 percent. The new phase 1 pilot study, PLAT-03, will examine the feasibility and safety of administering a second T-cell product intended to increase the long-term persistence of the patient's chimeric antigen receptor (CAR) T cells that were reprogrammed to detect and destroy cancer. In the PLAT-03 trial, patients will receive "booster" infusions of a second T-cell product, called T antigen-presenting cells (T-APCs). The T-APCs have been genetically modified to express the CD19 target for the cancer-fighting CAR T cells to recognize. Patients will receive a full dose of T-APCs every 28 days for at least one and up to six doses. By stimulating the CAR T cells with a steady stream of target cells to attack, researchers hope the CAR T cells will re-activate, helping to ensure their persistence long enough to put patients into long-term remission. PLAT-03 is now open to patients who first enroll in phase 2 of Seattle Children's PLAT-02 trial and who are also identified as being at risk for early loss of their reprogrammed CAR T cells, or those who lose their reprogrammed CAR T cells within six months of receiving them. The PLAT-03 trial is one of several trials that Seattle Children's researchers are planning to open within the next year aimed at further improving the long-term efficacy of T-cell immunotherapy. In addition to the current T-cell immunotherapy trial that is open for children with neuroblastoma, researchers also hope to expand this promising therapy to other solid tumor cancers.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|